RE:Rinse and RepeatSorry looks like I can't cut and paste but here were their forecasts from 2016:
TFC1067: 2016E
Upfront payment of $90M in Q2 (**)
2019E
Milestone payment of $98M (**)
2020E
Ongoing royalties totaling $715M (**)
Material Assumptions / Factors
Assumes exclusiveworldwide rights
•Peak penetration at year 10 = 15%.
•10 yearsales period from 2019 to 2028. (20 year patent protection).
Material Risk Factors
1067 is not licensed to a major corporation.
•Unfavorable testing results.
•Change in business priority of potential partner.
•Merger or acquisition of a potential partner creates unexpected delays.
TFC039 Diabetes projections: 2016E
$300K milestone payment in Q2
2017E
$500K upon IND filing
2018E
$500K
Phase I
2019E
$1.5M
Phase 3 CTA